Private equity-backed royalty deals, a relatively new edition to the biotech world, have already evolved from financing vehicle to strategic portfolio management tool. Now they seem to be evolving again, this time toward earlier-stage project financing, and they're starting to look a little like one of the oldest tricks in biotech's playbook: the Research and Development Limited Partnership (R&DLP). (BioWorld Today) Read More
